Evidence
earned, not claimed.
Every molecule we bring to market passes through hundreds of patients, dozens of investigators, and thousands of pages of documented proof.
The scale of our clinical evidence.
patients enrolled across our sponsored & partnered trials to date.
Ongoing trials worldwide
Investigator sites
Countries active
Published study reports
Every trial designed with the endpoint that matters — patient outcome.
Endpoint-driven design
Primary endpoints tied to real-world clinical benefit, not just statistical wins.
Data integrity first
eCRF, EDC, and blinded review — full ALCOA+ compliance on every field.
Patient-centric protocols
Reduced visit burden, digital consent, home-based follow-ups where safe.
From first-in-human to post-market surveillance.
Preclinical
n=animals
In-vitro, animal PK/PD
Phase I
20–100 healthy
Safety & dose finding
Phase II
100–500 patients
Efficacy signal
Phase III
1000–5000
Confirmatory pivotal
Phase IV
Real-world use
Post-marketing
Where our trials concentrate.
Cardiovascular
28 trials
Neurology & CNS
19 trials
Infectious Disease
22 trials
Metabolic & Diabetes
16 trials
Respiratory
12 trials
Oncology (Biosimilar)
9 trials
Pediatric Formulations
8 trials
Rare Disease
6 trials
A full-service CRO, without outsourcing.
Every participant. Every day. Watched over.
Independent Ethics Review
IRB approval before enrollment. No exceptions.
24/7 Adverse Event Line
Investigator hotline with 15-minute response SLA.
Informed Consent Standards
Multilingual, comprehension-tested, digital & paper.
DSMB Oversight
External Data Safety Monitoring Board for every pivotal trial.
42 investigator sites. One shared protocol.
From tertiary hospitals in Dhaka to community clinics in rural Kenya, our sites share unified electronic records, monitoring visits, and query resolution — so data quality is consistent whether the site enrolls 5 patients or 500.
Dhaka Medical College
BIRDEM Hospital
AIIMS New Delhi
Aga Khan Nairobi
King's College London
NUS Singapore
Frankfurt Uniklinik
ICDDR,B Field Sites
Real-time visibility, from the bedside to the biostatistician.
Recent trial highlights.
Nov 2025
Amoxicillin-Clavulanate BE study completed
n=42, DGDA BE filing successful
Sep 2025
Metformin XR pediatric trial — Phase III readout
Primary endpoint met with p<0.001
Jul 2025
Insulin glargine biosimilar Phase III initiated
6-country, 480-patient study underway
Apr 2025
Levetiracetam ODT — comparative bioavailability
Bioequivalence demonstrated vs innovator
Feb 2025
Ceftriaxone stability post-marketing surveillance
10,000+ patient real-world data collected
Interested in joining a trial?
Find a Study
Browse our active trials by condition, location, and eligibility.
Speak with Coordinator
A trained coordinator explains the study, risks, and your rights.
Enroll Safely
Sign consent, complete screening, and receive investigational care.
Peer-reviewed. Publicly indexed.
310+ peer-reviewed papers
The Lancet Global Health · 2025
Comparative efficacy of oral vs IV artemisinin in severe malaria
BMC Pediatrics · 2024
Palatability & adherence of pediatric amoxicillin dry syrup
Diabetes Care · 2024
Post-marketing safety of metformin XR in South Asian cohort
European Heart Journal · 2023
Atorvastatin 20mg — real-world adherence patterns
Antimicrob Agents Chemother · 2023
MIC drift monitoring for cephalosporins over 10 years
"I've worked with global CROs for two decades. What sets this team apart is how quickly protocol deviations are caught and resolved — often within the same 24-hour cycle. That's why our data holds up under regulatory scrutiny."
Prof. Nazma Kabir, MBBS FRCP
Principal Investigator, Dhaka Medical College Hospital
Compliance you can verify.
Sponsor a trial with a team that delivers.
Bioequivalence, Phase I–IV, post-marketing surveillance — we run studies for biotech innovators, generic manufacturers, and public health agencies across four continents.